Last reviewed · How we verify
Paclitaxel-trastzumab
At a glance
| Generic name | Paclitaxel-trastzumab |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (PHASE2)
- Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel-trastzumab CI brief — competitive landscape report
- Paclitaxel-trastzumab updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI